Japan Tissue Engineering Co Ltd
TSE:7774
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
EV/S
Enterprise Value to Sales (EV/S) ratio compares a company`s total enterprise value to its revenue. It shows how much investors are paying for each dollar of the company`s sales, including both equity and debt.
Enterprise Value to Sales (EV/S) ratio compares a company`s total enterprise value to its revenue. It shows how much investors are paying for each dollar of the company`s sales, including both equity and debt.
Valuation Scenarios
If EV/S returns to its 3-Year Average (8.1), the stock would be worth ¥531.92 (0% downside from current price).
| Scenario | EV/S Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 8.1 | ¥534 |
0%
|
| 3-Year Average | 8.1 | ¥531.92 |
0%
|
| 5-Year Average | 8.3 | ¥546.07 |
+2%
|
| Industry Average | 9.9 | ¥652.01 |
+22%
|
| Country Average | 1.1 | ¥73.07 |
-86%
|
Forward EV/S
Today’s price vs future revenue
| Today's Enterprise Value | Revenue | Forward EV/S | ||
|---|---|---|---|---|
|
¥25.1B
|
/ |
Jan 2026
¥2.3B
|
= |
|
|
¥25.1B
|
/ |
Mar 2026
¥3.9B
|
= |
|
|
¥25.1B
|
/ |
Mar 2027
¥5.1B
|
= |
|
Forward EV/S shows whether today’s EV/S still looks high or low once future revenue are taken into account.
Peer Comparison
| Market Cap | EV/S | P/E | ||||
|---|---|---|---|---|---|---|
| JP |
J
|
Japan Tissue Engineering Co Ltd
TSE:7774
|
21.7B JPY | 8.1 | -47 | |
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD | 33 691 034.4 | -160 127.7 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
348.9B USD | 6.6 | 83.3 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
183.4B USD | 6.1 | 23.7 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
158.5B USD | 5.8 | 18.8 | |
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR | 2 092.7 | -533.6 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
108.2B USD | 8.4 | 27.6 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
78.7B USD | 3.9 | 17.3 | |
| NL |
|
argenx SE
XBRU:ARGX
|
41.2B EUR | 10.5 | 37.3 | |
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR | 19.6 | -61.8 | |
| AU |
|
CSL Ltd
ASX:CSL
|
63.6B AUD | 3.4 | 30.3 |
Market Distribution
| Min | 0 |
| 30th Percentile | 0.7 |
| Median | 1.1 |
| 70th Percentile | 2 |
| Max | 12 107 466 |
Other Multiples
Japan Tissue Engineering Co Ltd
Glance View
Japan Tissue Engineering Co., Ltd. engages in the research, development, and manufacture of cultured biological cells and tissues. The company is headquartered in Gamagori-Shi, Aichi-Ken and currently employs 200 full-time employees. The company went IPO on 2007-12-21. The firm operates its business in two segments. The TEP segment is engaged in the research and development of self-cultured epidermis, self-cultured cartilages and self-cultured corneal epithelium for medical institutions. The Research and Development Supports segment is engaged in the development, manufacture and sale of laboratory human cultured tissues based on tissue engineering technology and manufacturing know-how for cosmetic and pharmaceutical product manufacturers.
